Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

thx frrol. that was an excellent post by O Neb. a keeper. along with the U of Colorado p53 researcher not being impressed with aprea, reinforces how Kevetrin is different, likely better, than the competition. bring on leo's biomarker update and the D Farber presentation at ASCO 2015.

thx too Infinity and rr. below some links to various MDM2-p53 articles, some of which i'm sure have been posted before. the first seems the best overview based on my cursory review --- comprehensive and gets to the MDM2-MDMX interplay. still learning up on the science.

///

Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics (2012)
http://1drv.ms/1GGSt04

xxxxxxxxxxxxx

MDM2-p53 Interaction in Peadiatric Solid Tumous: Preclinical Rationale, Biomarkers and Resistance (2014) (Note: this has been posted before / refs Kevetrin) (PDF)
http://www.ingentaconnect.com/content/ben/cdt/2014/00000015/00000001/art00010?crawler=true

Targeting MDM2-p53 interaction for cancer therapy: are we there yet? (2014) (abstract only)
http://www.ncbi.nlm.nih.gov/pubmed/24180275

Small molecule agents targeting the p53-MDM2 pathway for cancer therapy. (2012) (abstract only)
http://www.ncbi.nlm.nih.gov/pubmed/23059763

Targeting the MDM2–p53 interaction as a therapeutic strategy for the treatment of cancer (2010)
http://www.dovepress.com/targeting-the-mdm2ndashp53-interaction-as-a-therapeutic-strategy-for-t-peer-reviewed-article-CHC
http://www.dovepress.com/getfile.php?fileID=6660 (PDF, Full)

Targeting the MDM2-p53 Interaction for Cancer Therapy (2009)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676446/

The MDM2-p53 Interaction (2003)
http://mcr.aacrjournals.org/content/1/14/1001.full